Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome
Abstract T.M. Anoop Background The role of serum free light chain (FLC) as a prognostic biomarker in lymphoproliferative diseases is being increasingly studied. In this study we present the 5-year sur...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2022-07-01
|
| Series: | South Asian Journal of Cancer |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1743426 |
| _version_ | 1828084086406643712 |
|---|---|
| author | T.M. Anoop Geetha Narayanan Steffi Chacko K.M. Jagathnath Krishna Sreejith G. Nair |
| author_facet | T.M. Anoop Geetha Narayanan Steffi Chacko K.M. Jagathnath Krishna Sreejith G. Nair |
| author_sort | T.M. Anoop |
| collection | DOAJ |
| description | Abstract
T.M. Anoop
Background The role of serum free light chain (FLC) as a prognostic biomarker in lymphoproliferative diseases is being increasingly studied. In this study we present the 5-year survival outcome for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL) and their relation to FLC and other known prognostic markers.
Materials and Methods This is a prospective study conducted in patients diagnosed with aggressive B-cell NHL. Serum FLC level and ratio were estimated prior to initiation of treatment.
Results A total of 100 patients were included in the study from December 2013 to December 2015 with a median age of 53 years. Thirty-eight patients (38%) had elevated FLC level of which 26% were polyclonal and 12% were monoclonal elevations. Abnormal FLC ratio was noted in 12% patients. Median follow-up duration of the study was 75 months. Five-year relapse-free survival (RFS) for the study population was 54.4%. Five-year RFS was 64.1% for early stage and 48.2% for advanced stage diseases (p = 0.05). The RFS was significantly better in age less than 60 years (59.5% vs 43.8%, p < 0.001). Five-year overall survival (OS) was 61.3%. OS was significantly better in younger patients (73.6% vs 33.4%, p < 0.001), with International Prognosis Index score of 0 to 2 (87.4% vs 26.7%, p < 0.001). Patients with elevated FLC had inferior RFS (50% vs 71.4%, p = 0.04). Abnormal FLC ratio also strongly corresponded to inferior RFS (54.5% vs 66.2%, p = 0.001). OS was also significantly inferior in patients with abnormal FLC ratio (72.6% vs 63.6%, p = 0.001).
Conclusion In patients with newly diagnosed aggressive B-cell NHL, elevated FLC levels and abnormal FLC ratio were significantly associated with inferior survival. |
| first_indexed | 2024-04-11T04:19:27Z |
| format | Article |
| id | doaj.art-663083f4e0764bf1b08026660be223e9 |
| institution | Directory Open Access Journal |
| issn | 2278-330X 2278-4306 |
| language | English |
| last_indexed | 2024-04-11T04:19:27Z |
| publishDate | 2022-07-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | South Asian Journal of Cancer |
| spelling | doaj.art-663083f4e0764bf1b08026660be223e92022-12-31T00:30:45ZengThieme Medical and Scientific Publishers Pvt. Ltd.South Asian Journal of Cancer2278-330X2278-43062022-07-01110325625910.1055/s-0042-1743426Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival OutcomeT.M. Anoop0Geetha Narayanan1Steffi Chacko2K.M. Jagathnath Krishna3Sreejith G. Nair4Department of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, IndiaDepartment of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, IndiaDepartment of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, IndiaDepartment of Epidemiology and Biostatistics, Regional Cancer Center, Thiruvananthapuram, Kerala, IndiaDepartment of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, IndiaAbstract T.M. Anoop Background The role of serum free light chain (FLC) as a prognostic biomarker in lymphoproliferative diseases is being increasingly studied. In this study we present the 5-year survival outcome for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL) and their relation to FLC and other known prognostic markers. Materials and Methods This is a prospective study conducted in patients diagnosed with aggressive B-cell NHL. Serum FLC level and ratio were estimated prior to initiation of treatment. Results A total of 100 patients were included in the study from December 2013 to December 2015 with a median age of 53 years. Thirty-eight patients (38%) had elevated FLC level of which 26% were polyclonal and 12% were monoclonal elevations. Abnormal FLC ratio was noted in 12% patients. Median follow-up duration of the study was 75 months. Five-year relapse-free survival (RFS) for the study population was 54.4%. Five-year RFS was 64.1% for early stage and 48.2% for advanced stage diseases (p = 0.05). The RFS was significantly better in age less than 60 years (59.5% vs 43.8%, p < 0.001). Five-year overall survival (OS) was 61.3%. OS was significantly better in younger patients (73.6% vs 33.4%, p < 0.001), with International Prognosis Index score of 0 to 2 (87.4% vs 26.7%, p < 0.001). Patients with elevated FLC had inferior RFS (50% vs 71.4%, p = 0.04). Abnormal FLC ratio also strongly corresponded to inferior RFS (54.5% vs 66.2%, p = 0.001). OS was also significantly inferior in patients with abnormal FLC ratio (72.6% vs 63.6%, p = 0.001). Conclusion In patients with newly diagnosed aggressive B-cell NHL, elevated FLC levels and abnormal FLC ratio were significantly associated with inferior survival.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1743426free light chainnon-hodgkin's lymphomasurvivalaggressive b-cell nhlprognostic biomarker |
| spellingShingle | T.M. Anoop Geetha Narayanan Steffi Chacko K.M. Jagathnath Krishna Sreejith G. Nair Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome South Asian Journal of Cancer free light chain non-hodgkin's lymphoma survival aggressive b-cell nhl prognostic biomarker |
| title | Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome |
| title_full | Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome |
| title_fullStr | Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome |
| title_full_unstemmed | Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome |
| title_short | Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome |
| title_sort | serum free light chain assay as a prognostic marker in patients with aggressive b cell non hodgkin s lymphoma impact on survival outcome |
| topic | free light chain non-hodgkin's lymphoma survival aggressive b-cell nhl prognostic biomarker |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1743426 |
| work_keys_str_mv | AT tmanoop serumfreelightchainassayasaprognosticmarkerinpatientswithaggressivebcellnonhodgkinslymphomaimpactonsurvivaloutcome AT geethanarayanan serumfreelightchainassayasaprognosticmarkerinpatientswithaggressivebcellnonhodgkinslymphomaimpactonsurvivaloutcome AT steffichacko serumfreelightchainassayasaprognosticmarkerinpatientswithaggressivebcellnonhodgkinslymphomaimpactonsurvivaloutcome AT kmjagathnathkrishna serumfreelightchainassayasaprognosticmarkerinpatientswithaggressivebcellnonhodgkinslymphomaimpactonsurvivaloutcome AT sreejithgnair serumfreelightchainassayasaprognosticmarkerinpatientswithaggressivebcellnonhodgkinslymphomaimpactonsurvivaloutcome |